Novo Nordisk raises 2026 outlook as Wegovy pill beats forecasts
Novo Nordisk said third-quarter sales of its Wegovy pill reached 5.39-billion Danish crowns, above the 4.62-billion analysts expected. Sales rose 53% on the second quarter, and the drugmaker raised its 2026 outlook for the third time.
Novo Nordisk now expects 2026 adjusted sales and adjusted operating profit to move between a 2% rise and a 2% fall at constant exchange rates. Its earlier forecast was a fall of 0% to 6%. The company said higher expectations for GLP-1 sales in the US and international markets drove the change.
US sales of the pill were 4.18-billion Danish crowns, and international sales were 1.22-billion. About 3.6-million prescriptions were filled in the US in the quarter, and more than 8-million since launch. Adjusted sales were 79.20-billion crowns, against 73.22-billion expected. Adjusted operating profit was 31.72-billion crowns, against 28.39-billion projected by analysts.
Sales of injectable Wegovy in the US fell 13% at constant exchange rates, but combined US Wegovy sales rose 21%. Chief executive Mike Doustdar said growth was led by the obesity portfolio. Analysts said the pill is the company's main route back to growth.
Key facts
- Who
- Mike Doustdar (CEO of Novo Nordisk); Novo Nordisk (drug maker reporting the results); Eli Lilly (US rival drug maker)
- What
- Novo Nordisk reported third-quarter sales of its Wegovy pill above analyst consensus, with sales up 53% on the second quarter, and raised its 2026 adjusted sales and operating profit guidance for the third time. The company said the improvement was driven by higher expectations for GLP-1 sales in the US and international markets.
- When
- 4 November 2026
- Where
- United States, Denmark
- Status
- Reported